Intellia Therapeutics' Phase 3 HAELO trial demonstrated that a single 50mg infusion of Lonvoguran, an in vivo CRISPR therapy targeting the KLKB1 gene, achieved 87% attack free rates over six months in hereditary angioedema patients—a significant improvement over the 11% placebo…
For most of her adult life, Maria Fernandez kept a hospital bag next to her front door. The 34-year-old teacher from Ohio has hereditary angioedema — a rare genetic disorder that causes sudden, potentially life-threatening swelling attacks in the throat, abdomen, or extremities, with little warning and no reliable way to stop them. A new clinical trial result suggests the disease itself might finally be something she can eliminate.
The treatment is a CRISPR-based gene edit — a single infusion that, if approved, would rewrite the genetic instructions driving her attacks directly inside the body. Intellia Therapeutics reported Phase 3 results Monday showing that 87 percent of patients like Fernandez were attack-free for six months, and more than 60 percent had no attacks at all during that period. The company's stock fell 3 percent, according to Investing.com.
The data, by any conventional measure, are striking. Hereditary angioedema attacks strike roughly 1 in 50,000 people — most patients endure several per month, and some die from throat swelling before they can reach treatment. In Intellia's HAELO trial, patients receiving a single 50-milligram dose had a mean monthly attack rate of 0.26, compared with 2.10 for those on placebo, Investing.com reported. Sixty-one percent were entirely attack-free over the six-month study window, versus 11 percent in the placebo group, according to STAT News.
CRISPR, the gene-editing tool that lets scientists cut and rewrite DNA sequences, is not new to medicine. The first approved CRISPR treatment, Vertex Pharmaceuticals' Casgevy, cleared the FDA in late 2023 for sickle cell disease and beta thalassemia. But Casgevy works ex vivo: doctors extract a patient's cells, edit them in a lab, then reinfuse them. Intellia's treatment, to be called Lonvoguran if approved, works in vivo — the gene editor circulates directly in the bloodstream, reaching its target inside the body.
"Editing genes inside the body is the harder engineering problem," said Dr. James Wilson, a gene therapy researcher at the University of Pennsylvania who was not involved in the trial. "Getting precision without the extraction step changes what you can reach."
Intellia has already initiated a rolling submission with the FDA, with a biologics license application expected in the second half of 2026, STAT News reported. If approved, Lonvoguran would be the second approved CRISPR medicine and the first in-vivo one. It targets the KLKB1 gene, which encodes a protein that triggers the swelling cascade in hereditary angioedema — disabling that gene effectively stops the attacks at their source, according to Intellia's investor relations page.
The Phase 1 and 2 data, reported separately, showed durability that suggests this might be a one-time cure for many patients: 97 percent of participants on the highest dose were attack-free for up to three years after a single infusion, with a 96 percent reduction in monthly attack rate, ts2.tech reported. The Phase 3 result confirmed those numbers at larger scale, according to STAT News.
The complication is that Intellia's stock fell anyway. Investors are watching a separate program — Nex-Z, the company's experimental treatment for ATTR amyloidosis, a fatal protein-folding disorder — which ran into trouble last year when a patient died from a Grade 4 liver adverse event, CGTlive reported. The FDA lifted the clinical hold on the MAGNITUDE-2 trial in January 2026 and on the MAGNITUDE trial in March 2026, GlobeNewsire reported, and both trials have resumed enrollment with enhanced liver monitoring. The patient death is still under investigation, and it is unclear whether the liver toxicity signal is specific to Nex-Z or a broader class risk for Intellia's editing approach. The two programs use the same in-vivo delivery technology, which is why the market is parsing the hereditary angioedema results so carefully despite their strength.
"The data are real and the regulatory path looks clean — nobody is disputing that," said a healthcare analyst who covers NTLA for a major investment bank. "The question is whether Nex-Z is an isolated case or the beginning of a pattern."
Intellia ended 2025 with $605 million in cash and equivalents, which the company says extends its runway into the second half of 2027, ts2.tech reported. That gives the company time to work through the Nex-Z investigation and potentially launch Lonvoguran before it needs additional capital. The company declined to comment beyond its public statements.
What the HAELO data suggest, if the FDA agrees, is that in-vivo CRISPR has cleared its biggest regulatory hurdle — proving that a single, permanent genetic edit delivered inside the body can durably eliminate a chronic disease without unacceptable safety risks. Whether that message survives the Nex-Z shadow is the question Intellia now has to answer.
If Lonvoguran clears the in-vivo CRISPR template, Intellia's hemophilia program and other single-gene pipeline candidates become more credible prospects — not just rare-disease experiments but the leading edge of a broader platform. The HAELO proof of concept arrives first in hereditary angioedema, a small market by most estimates, but one where the unmet need is severe and the biology is well-understood.
Lonvoguran does not yet have a price, and it will almost certainly cost more than most drugs on the market today — the field has not yet established what a one-time CRISPR cure is worth to insurers or health systems. That debate is coming. For now, the scientific question has been answered: the approach works. The next question is whether the company can convince a skittish market that Nex-Z's liver death was an anomaly, not a class warning.
The first patient who might receive it, if everything goes well at the FDA, is someone like Maria Fernandez — a teacher in Ohio who has spent her adult life waiting for the phone call that means the next attack is coming. The gene edit she might receive would be permanent. So would the consequence if the liver safety questions aren't resolved first.